



# MARKET RELEASE

22 April 2015

**Actinogen Limited**

**TRADING HALT**

The securities of Actinogen Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday 24 April, 2015 or when the announcement is released to the market.

Security Code: ACW

Jill Hewitt  
**Senior Adviser, Listings Compliance (Perth)**



22 April 2015

Ms Anjuli Sinniah  
ASX Operations  
Level 40 Central Park  
152-158 St George's Terrace  
PERTH WA 6000

*Via Email*

Dear Anjuli

## **Trading Halt Request**

In accordance with ASX Listing Rule 17.1, the Company hereby requests that its securities be placed into an immediate trading halt pending an announcement regarding a capital raising for a Phase II study in Alzheimer's dementia.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Friday, 24 April 2015, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a light grey rectangular background.

**Peter Webse**  
Company Secretary

### **About Actinogen Medical**

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer's disease and prodromal Alzheimer's/Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat Alzheimer's disease and other age-related neurodegenerative diseases. The lead candidate Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results expected in mid-2015. Actinogen Medical plans to initiate a Phase II study in Alzheimer's and Mild Cognitive Impairment in 2016.